Dec 8 2025
David Kuter gave this presentation at ASH 2025:
Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression.
Increase Platelet Production
- The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration.
Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefine our strategy:
- Anti-CD38 antibodies (daratumumab, mezagitamab)
- BAFF/BAFF-R inhibitors
- FcRn inhibitors (efgartigimod)
- BTK inhibitors (rilzabrutinib, orelabrutinib)
- Complement inhibitors + immunomodulatory approaches
- T-cell engagers & CAR-T therapies
Click here for slides on platelet production and platelet destruction
Comments (0)
Bleeding Disorders
No comments here.